Table 1.
Demographic and clinical characteristics of study participants
| Schizophrenia (N=59) | Control (N=36) | Statistics t/z/χ 2 | P Value | |
|---|---|---|---|---|
| Gender, M/F | 17/42 | 16/20 | 2.410 | 0.121 |
| Age (yrs) | 38.07±10.57 | 38.03±9.66 | 0.018 | 0.985 |
| Education (yrs) | 12.42±3.45 | 13.22±3.64 | -1.220 | 0.222 |
| Marital status, Single/Married | 43/16 | 8/28 | 23.08 | <0.001 |
| Smoking, Y/N | 8/51 | 5/31 | 0.002 | 0.964 |
| BMI (kg/m2) | 21.66±3.89 | 24.42±3.62 | -3.443 | 0.001 |
| Illness duration (mos) | 53.61±63.41 | NA | NA | NA |
| PANSS | ||||
| P subscore | 25.76±4.83 | NA | NA | NA |
| N subscore | 20.76±7.17 | NA | NA | NA |
| G subscore | 42.54±7.38 | NA | NA | NA |
| Total score | 89.07±14.32 | NA | NA | NA |
| PSQI | ||||
| Subjective sleep quality | 1.27±0.94 | 0.67±0.79 | -3.112 | 0.002 |
| Sleep latency | 1.32±1.11 | 0.72±0.91 | -2.656 | 0.008 |
| Sleep duration | 0.83±1.02 | 0.78±0.83 | -0.059 | 0.953 |
| Sleep efficiency | 0.81±1.09 | 0.31±0.58 | -2.209 | 0.027 |
| Sleep disturbances | 0.81±0.51 | 0.67±0.48 | -1.319 | 0.187 |
| Sleep medication use | 1.48±1.49 | 0.17±0.61 | -4.408 | <0.001 |
| Daytime dysfunction | 1.37±1.19 | 0.86±0.90 | -1.975 | 0.048 |
| Total score | 7.78±4.39 | 4.14±3.60 | -4.139 | <0.001 |
| FPG (mmol/L) | 4.89±1.09 | 5.06±0.33 | -2.440 | 0.015 |
| TC (mmol/L) | 4.57±1.05 | 4.93±0.79 | -1.780 | 0.078 |
| TG (mmol/L) | 1.15±0.72 | 1.29±1.05 | -0.307 | 0.759 |
| HDL-C (mmol/L) | 1.42±0.39 | 1.40±0.33 | -0.008 | 0.994 |
| LDL-C (mmol/L) | 2.66±0.78 | 2.82±0.78 | -1.004 | 0.318 |
NA Not applicable, PANSS Positive and Negative Syndrome Scale, P subscore Positive symptom subscore, N subscore Negative symptom subscore, G subscore General psychopathology subscore, PSQI Pittsburgh Sleep Quality Index, BMI Body mass index, FPG Fasting plasma glucose, TC Total Cholesterol, TG Triglyceride, HDL-C High-density lipoprotein cholesterol, LDL-C Low-density lipoprotein cholesterol